Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462234 | 0.92 | SLC6A9 (0.58) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL1382988 | 0.88 | SLC6A9 (0.58) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3875974 | 0.82 | SLC6A9 (0.65) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3872951 | 0.81 | SLC6A9 (0.64) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4798211 | 0.81 | SLC6A9 (0.69) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3876340 | 0.81 | SLC6A9 (0.69) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL1379673 | 0.79 | SLC6A9 (0.66) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3874149 | 0.79 | SLC6A9 (0.64) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL3946327 | 0.79 | SLC6A9 (0.79) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL8261794 | 0.77 | SLC6A9 (0.56) | SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101146808-B | Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| CN-101146808-A | Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | CN | disclosed |
| EP-1844045-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | SLC6A9 12/4885KCNH2 977/4885SLC6A5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.